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Abstract: combined photochemical arylation, “nuisance effect” (SNAr) 
reaction sequences have been employed in the design of small arrays 
for immediate deployment in medium throughput X-ray protein-ligand 
structure determination. Reactions have been deliberately let “out of 
control,” in terms of selectivity; for example the ortho-arylation of 2-
phenylpyridine gave five products resulting from mono-, bis- arylations 
combined with SNAr processes.  As a result, a number of 
crystallographic hits against NUDT7, a key peroxisomal CoA ester 
hydrolase, have been identified. 
Introduction 
Given their atom and step economy, C-H activation processes are 
now commonplace in organic synthesis[1]. Highly decorated 
bioactive or synthetically relevant molecules can be functionalized 
via a late stage activation process, enabling the efficient 
production of derivatives for e.g. structure activity studies or 
pharmacokinetic evaluation, saving significant time and cost 
compared to previous cumbersome multistep syntheses[2–14]. 
We have recently disclosed our findings on the microwave 
mediated ortho-C-H activation of benzodiazepines using 
iodonium salts under Pd catalysis (Figure 1)[15]. These processes 
tend to give monoarylated products although, under more forcing 
conditions, a second ortho-arylation was observed.  Recent, 
complementary, studies on the visible light mediated “Sanford” 
arylation[16–18] of benzodiazepines using diazonium salts and dual 
Ru/Pd catalysis led mainly to mono-functionalized product[19]. 
However, in the case of 2- or 4- substituted fluoro-benzene 
diazonium salt coupling partners, further competing SNAr 
reactions were observed (“nuisance effect”), when a nucleophilic 
solvent such as methanol or ethanol was used.  
Figure 1. Examples of diverse benzodiazepines formed from 
ortho C-H activation processes. 
 
Such a spectrum of reactivity opens up scope for performing ortho 
C-H activations with complete control, driving towards the 
formation of a single product in a highly efficient manner (see A, 
Scheme 1). Conversely, from the previous example (Figure 1), 
erosion of selectivity via the competing formation of bis-arylated 
product, as in B or even total loss of control, as in C, where the 
coupling partner has a group (Y in Scheme 1) capable of further 
functionalisation, can also be envisioned. Outcome A is irrefutably 
catalysis friendly whereas C might be more appropriate in a 
medicinal chemistry setting, where making small arrays with 
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minimal work-up bottlenecks is desirable, given the high 
compound attrition and cost of drug discovery.  
 
Scheme 1. Extremes of reactivity scenarios in ortho C-H 
activation chemistry with varying degrees of control. R1-Y is a 
coupling partner with a group, Y, capable of further reactivity; X is 
a halogen or diazonium group. 
 
It was our intention to undertake a proof of principle feasibility 
study of the development of C-H activation chemistry capable of 
losing control, in the selectivity (not health and safety) context, 
creating small arrays and diverse mixtures of compounds for 
immediate deployment in a medicinal chemistry setting with 
minimal work up or purification[20–23]. To assist in the process, 
protein crystallographic screening of the small arrays vs a key 
peroxisomal protein of current interest was used as a means of 
validating this approach (vide infra). 
 
1. Results and Discussion 
We chose 1-phenylpyrrolidin-2-ones as a starting point given their 
low molecular weight, potential as drug-like fragments as well as 
their known ability to undergo C-H activation. Controlled Sanford 
arylations of diazonium salts on 1-phenylpyrrolidin-2-one using 
dual Pd/Ru catalysis and slightly modified standard literature 
conditions (reflux vs. ambient temperature)[17], in our hands, led 
to one major product 3, in good to excellent yields (Scheme 2).  
 
Scheme 2. Controlled Arylations. 
 
Next, we tested the possibility of losing control by performing 
nuisance effect reactions on the fluorodiazonium salt 2a (Table 1) 
where there is a possibility of an SNAr reaction on 2a prior to the 
CH activation. The best conditions (entry 1) gave excellent 
conversion and a good 75% combined isolated yield of 3f and 3a. 
In entry 2, higher conversions of 3g were found but with a lower 
overall yield of 3f. Entries 4 and 5 are in line with the earlier work 
of Sanford et al., who obtained a 62% conversion to 3 in the 
absence of a Ru catalyst, at ambient temperature, whereas 
entries 3 and 6 show that low conversions are observed in the 
absence of light. It was anticipated that the ratio of the products 
could be influenced by the sequence in which the reactions were 
performed; for instance, the ratio of the ether to fluoro products, 
3a vs 3f, was significantly increased when 2a was heated to reflux 
in methanol first, to initiate the SNAr process (entry 7) prior to the 
addition of the other reagents. 
 






Temp.  Conversion 
LC-MS (%) 
(3f:3a) 
1 a 2.5 reflux 85 (4:1) 
2 b 2.5 reflux 60 (2:1) 
3 c 2.5 reflux 25 (2:1) 
4 a - reflux 65 (6:1) 









                      
       20 (99: 
trace) 
         31 
(1:4)d 
                 
a 26W compact fluorescent light bulb, b daylight. c in absence of 
light. d 2a and MeOH were refluxed first (1h) then the other 
components were added and reacted for 4h. 
 
Using the optimized conditions, a small array of arylated products 
was formed (Scheme 3). Interestingly, under identical conditions, 
a higher ratio of the ether product from ethanol was achieved in 
comparison with methanol, i.e. 3g vs. 3a. The reaction of i-PrOH 
gave a low yield of 3h, which was obtained as an inseparable 
mixture with 3f. Unsurprisingly, ortho-substituted analogues 3i 
and 3j can also be synthesised.  




Scheme 3. 1-Phenylpyrrolidin-2-one derivatives (isolated yields) 
from C-H activation/nuisance effect reactions. 
 
Next, a one-pot reaction, employing a mixture of alcohols, led to 
a small array of ether products alongside the expected 
fluorobiphenyl 3f (Scheme 4). We did not observe any significant 
bis-arylations in these reactions and the array was subjected, 
without purification, to an X-ray protein crystallographic analysis. 
Scheme 4. Losing control: small array of 1-phenyl-2-pyrrolidinone 
derivatives formed from a mixture of alcohols. 
Similarly, a small array of monoarylated compounds can be 
produced by using a mixture of diazonium salts. The mixture of 
products was deployed immediately in an X-ray protein 
crystallographic screen without any further purification (vide infra) 
(Scheme 5). 
 
Scheme 5. Synthesis of a small array from mixture of diazonium 
salt precursors. a LC-MS conversion rates. 
To test the limits of this chemistry, i.e. scenario C in Scheme 1, 
we attempted out of control reactions on a different scaffold, 
namely 2-phenylpyridine 4. This was partly driven by the fact that 
scaffold 1 did not lead to any observed bis-arylations. Interestingly, 
many literature C-H activations on 4 are carried out on methylated 
phenylpyridines, presumably to limit reactivity to a single 
arylation[17,18]. 
Reaction of 4 with excess 4-fluorodiazonium salt was carried out 
under reflux in methanol and gratifyingly led to five products 5a – 
5e, resulting from a combination of mono, di-arylation and 
combined “nuisance effects” i.e “no control” (Scheme 6). The 
components were separable or were subjected, as a crude 
mixture/small array, for protein X-ray studies.  
 
Scheme 6. Out of control small array of 2-phenylpyridine 
derivatives from combined C-H arylation and nuisance effects. 
This process is somewhat limited i.e. just the three alcohols tried, 
other nucleophiles e.g. thiols gave mixed results and similar C-H 
activation attempts with simple benzamides in methanol, such as 
N-phenylacetamide, N-methyl-N-phenylacetamide2,2‐dimethyl‐
N‐phenylpropanamide and N,2,2‐trimethyl‐N‐phenylpropanamide, 
led predominantly to bis(4‐methoxyphenol)diazene. Solvent 
screens gave little improvement or any extra SNAr scope, e.g. 
DCE, 1,4-dioxane, DME, xylenes, i-PrOH, t-BuOH, DMSO, MeCN, 
phenol, and acetone led to little change in yields in these 
processes.  
The above arrays were subjected to X-ray crystallographic 
evaluation against NUDT7, a member of the superfamily of 
enzymes, Nudix hydrolases, which, hydrolyse a wide range of 
pyrophosphates and are thought to act as cellular 
“housecleaners.”[24,25]  Two isoforms of NUDT7 have been 
identified: NUDT7 and NUDT7. The former is a peroxisomal 
CoA ester diphosphatase, whereas NUDT7 is an inactive splice 
variant[26]. NUDT7  regulates CoA metabolism by hydrolysing 
CoA esters to various fatty acids of varying chain lengths of acyl-
phosphopantetheines and 3’,5’-ADP[27–29]. Recently, the 
upregulation of NUDT7 has been implicated in high risk of 
inflammatory bowel disease, colorectal cancer and pantothenate 
kinase-associated neurodegeneration (PKAN)[30][31].  
All arrays above were submitted for X-ray analysis; of note, only 
3f was detected from the small array shown with 3a and 3c 
(Scheme 5).[32]  Individually purified, compounds 3a, 3c, 3d and 
3f were found to crystallise in NUDT7 (Figure 2) involving 
predominantly van der Waals interactions.  
 
 




Figure 2. Crystal structures of NUDT7 in complex with compounds 3a, 3c, 3d and 3f. (a) Cartoon representation of ligand-free 
NUDT7 with the NUDIX box coloured in cyan. The compound binding region is highlighted by with a red square. (b-e) Magnified views 
of the bound compounds: (b) compound 3a (PDB iD 5QGM); (c) compound 3c (PDB ID 5QHC); (d) compound 3d (PDB ID 5QHB); (e) 
compound 3f (PDB ID 5QHE). 
 
An overlay of independent X-ray co-crystals of 3a and an 
independent carbamate fragment NU181 showed their proximity 
in the binding pocket and a potential fragment merging 
opportunity (Figure 3). 
 
Figure 3. Overlay of NUDT7  in complex with compound 3a 
(PDB ID 5QGM) and in complex with NU181 (PDB ID 5QH1). 
The protein structure of 5QH1 is omitted for clarity. 
Thereafter, we attempted to merge the two fragments with the aim 
of improving activity as well as to combine covalent binding due 
to the presence of a proximal Cys residue (C73) in the protein.[33] 
Demethylation of 3a was achieved using boron tribromide to 
afford 3k, which, upon attempted reaction with an isocyanate, led 
to an insoluble mixture.  
 
Scheme 7. Demethylation of 3a. 
Next, the 4-nitrobiaryl pyrrolidinone compound 3e was reduced to 
aniline 3l using tin(II) chloride dihydrate and was further 
functionalized (Scheme 8) to afford the maleimide 3m and the 
amides 3n and 3o respectively. As with the desired carbamate 
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synthesis (Scheme 7), the attempted synthesis of a urea product 
was hampered by the formation of an inseparable mixture of 
insoluble products. 
 
Scheme 8. Functionalization of 1-(4’-aminobiphenyl-2-
yl)pyrrolidin-2-one, 3l. a) SnCl2.2H2O, EtOAc, 70oC, o/n; b) 
chloroacetyl chloride, Et3N, CH2Cl2, o/n; c) chlorobenzoyl 
chloride, Et3N, CH2Cl2, o/n; d) 3-chlorophenyl isocyanate, Et3N, 
CH2Cl2, o/n; e) i. maleic anhydride, CHCl3, 2h ii. Acetic anhydride, 
sodium acetate, 2h, reflux. 
 
Unfortunately, none of these compounds described, including 3n 
- 3o, above displayed any appreciable binding in a SPR assay 




This proof of principle study has shown that it is indeed possible 
to get “more bang for your buck” by allowing C-H activations to 
lose a certain degree of control.  By creating small arrays for 
immediate deployment in biological studies, purification 
bottlenecks are reduced and direct X-ray analysis vs new protein 
targets of interest are indeed possible. This study is, nevertheless 
limited to a narrow range of chemically-similar directing group-
containing substrates, a few alcohols as nucleophiles and and 
also relies on an x-ray screening of impure mixtures since not all 
techniques are that tolerant. However, it may highlight the need 
to check for competing “nuisance effect” reactions when using 
fluorobenzene diazonium salts in alcoholic solutions. It 
nevertheless gives us the confidence to try larger, more diverse 
arrays in biological studies. Results of these endeavours are 




All commercially purchased materials and solvents were used 
without further purification unless specified otherwise. NMR 
spectra were recorded on a Varian VNMRS 500 (1H 500 MHz, 13C 
126 MHz) spectrometer and prepared in deuterated solvents such 
as CDCl3 and DMSO-d6. 1H and 13C chemical shifts were 
recorded in parts per million (ppm). Multiplicity of 1H-NMR peaks 
are indicated by s – singlet, d – doublet, dd – doublets of doublets, 
t – triplet, pt – pseudo triplet, q – quartet, m – multiplet and 
coupling constants are given in Hertz 
(Hz).  Electronspray ionisation – high resolution mass spectra 
(ESI-HRMS) were obtained using a Bruker Daltonics Apex III 
where Apollo ESI was used as the ESI source. All analyses were 
conducted by Dr A. K. Abdul-Sada. The molecular ion peaks [M]+ 
were recorded in mass to charge (m/z) ratio. LC-MS spectra were 
acquired using Shimadzu LC-MS 2020, on a Gemini 5 m C18 
110 Å. column. All X-ray analyses were performed at the UK 
National Crystallography Services, Southampton. Purifications 
were performed by flash chromatography on silica gel columns or 
C18 columns using a Combi flash RF 75 PSI, ISCO unit.  
 
1-(4’-Fluorobiphenyl-2-yl)pyrrolidin-2-one (3f); 1-(4’-
Methoxybiphenyl-2-yl)pyrrolidin-2-one (3a) “Standard method.” 
1-Phenyl-2-pyrrolidinone (0.065 g, 0.40 mmol), 4-
fluorobenzenediazonium tetrafluoroborate (0.35 g, 1.67 mmol), 
palladium (II) acetate (0.009 g, 0.04 mmol) and Ru(bpy)3Cl2.6H2O 
(0.007 g, 0.01 mmol) were suspended in degassed, anhydrous 
methanol (4 mL). Two fluorescent light bulbs (26 W) were placed 
on either side of the reaction vessel and the reaction mixture was 
heated at reflux for 4 hours under inert atmosphere. The reaction 
mixture was allowed to cool to ambient temperature, diluted with 
ethyl acetate (50 mL) and washed with water (20 mL) and 
aqueous sodium sulphite (10%, 35 mL x 2). The combined 
aqueous layers were extracted with ethyl acetate (50 mL) and 
thereafter the combined organic layer was washed with brine (50 
mL), dried (MgSO4) and concentrated under reduced pressure. 
The resulting crude material was purified by reversed phase 
chromatography (water/acetonitrile with 0.1% formic acid, 5 min 
at 0%, 30%-90%). The reaction generated two products, 3f was 
obtained as a viscous oil (0.062 g, 61%) and 3a was obtained also 
as a viscous oil (0.015 g, 14%). The spectral data were concurrent 
with those reported.16 
 
1-(4’-Methoxybiphenyl-2-yl)pyrrolidin-2-one (3a) 
3a was synthesised on a bigger scale by combining 1-phenyl-2-
pyrrolidinone (0.50 g, 3.1 mmol), 4-methoxybenzenediazonium 
tetrafluoroborate (2.75 g, 12.4 mmol), palladium (II) acetate 
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(0.069 g, 0.31 mmol) and Ru(bpy)3Cl2.6H2O (0.58 g, 0.078 mmol) 
were suspended in degassed, anhydrous methanol (30 mL). Two 
fluorescent light bulbs (26 W) were placed on either side of the 
reaction vessel and the reaction mixture was heated at reflux for 
4 hours under inert atmosphere. The reaction mixture was 
allowed to cool to ambient temperature, diluted with ethyl acetate 
(50 mL) and washed with water (20 mL) and aqueous sodium 
sulphite (10%, 35 mL x 2). The combined aqueous layers were 
extracted with ethyl acetate (50 mL) and thereafter the combined 
organic layer was washed with brine (50 mL), dried (MgSO4) and 
concentrated under reduced pressure. The resulting crude 
material was purified by reversed phase chromatography 
(water/acetonitrile with 0.1% formic acid, 5 min at 0%, 30%-90%). 
Product 3a was obtained as a viscous oil (0.64 g, 77%). 
 
1-(4’-Ethoxybiphenyl-2-yl)pyrrolidin-2-one (3g) 
The standard method was used except that ethanol (5 mL) was 
used as the solvent instead of methanol.  Starting material, 1-
phenyl-2-pyrrolidinone (0.007 g, 0.043 mmol) was recovered and 
two products were generated, product 3f was obtained as an oil 
(0.038 g, 42%) and product 3g was obtained also as an oil (0.028 
g, 28%). 1H-NMR (500 MHz) CDCl3: δ = 7.40 – 7.34 (m, ArH, 3H), 
7.33 – 7.28 (m, ArH, 3H), 6.93 (d, 3JHH = 8.5 Hz, ArH, 2H), 4.08 
(q, 3JHH = 7.0 Hz, O-CH2CH3, 2H), 3.23 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2N, 2H), 2.44 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 
2H), 1.89 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H), 1.45 (t, 3JHH = 
7.0 Hz, O-CH2CH3, 3H). 13C-NMR (126 MHz) CDCl3: δ = 175.6 
(C=O), 158.6 (ArC), 139.4 (ArC), 136.4 (ArC), 131.4 (ArC), 130.9 
(ArC), 129.5 (2 x ArC), 128.4 (ArC), 128.1 (ArC), 127.9 (ArC), 
114.4 (2x ArC), 63.5 (O-CH2CH3), 50.1 (COCH2CH2CH2N), 31.2 
(COCH2CH2CH2N), 19.0 (COCH2CH2CH2N), 14.8 (O-CH2CH3). 
HRMS-ESI (m/z) calculated for C18H19NO2 [+H] +: 282.1489, 
found: 282.1487. LCMS purity (UV) = 97 %, tR 11.85 min. 
 
1-(4’-Isopropoxybiphenyl-2-yl)pyrrolidin-2-one (3h) 
The usual method was used but 2-propanol (5 mL) was used as 
the solvent instead of methanol. Starting material, 1-phenyl-2-
pyrrolidinone (0.027 g, 0.17 mmol) was recovered and two 
products were generated, product 3f was obtained as a white 
solid (0.019 g, 32%) and a mixture of 3f and 3h was obtained an 
oil (0.0059 g, 9%) in 1:4 ratio as determined by 1H-NMR and LC-
MS.  
 
3f/3h mixture: 1H-NMR (500 MHz) CDCl3: δ = 7.62 – 7.52 (m, ArH, 
1H), 7.42 – 7.35 (m, ArH, 4H), 7.32 – 7.26 (m, ArH, 3H), 6.91 (d, 
3JHH = 8.5 Hz, ArH, 2H), 4.62 – 4.55 (m, O-CHCH3CH3, 1H), 3.92 
(t, 3JHH = 7.0 Hz, COCH2CH2CH2N, 1H), 3.22 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2N, 2H), 2.64 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N  
1H), 2.44 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N x 4, 8H), 2.23 – 2.16 
(m, COCH2CH2CH2N, 1H), 1.90 (q, 3JHH = 7.5 Hz, 
COCH2CH2CH2N, 2H), 1.37 (d, 3JHH = 6.0 Hz, O-CHCH3CH3, 6H). 
HRMS-ESI (m/z) calculated for C19H21NO2 [+H] +: 296.1650, 
found: 296.1647. LCMS ratio (UV) = 3h 18%, tR 12.37 min, 3f, 




This reaction was performed on a 0.30 mmol scale by the general 
procedure but with 2-fluorobenzenediazonium tetrafluoroborate 
(0.25 g, 1.20 mmol). Starting material, 1-phenyl-2-pyrrolidinone 
was recovered (0.006 g, 0.037 mmol) and two products were 
generated; product 3i was obtained as a viscous oil (0.022 g, 
32%) and 3j was obtained as a viscous oil (0.027 g, 39%).3i: 1H-
NMR (500 MHz) CDCl3: δ = 7.46 – 7.42 (m, ArH, 1H), 7.41 – 7.37 
(m, ArH, 2H), 7.36 – 7.31 (m, ArH, 3H), 7.20 – 7.16 (m, ArH, 1H), 
7.15 – 7.10 (m, ArH, 1H), 3.39 (t, 3JHH = 7.0 Hz, COCH2CH2CH2N, 
2H), 2.35 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.91 (p, 3JHH = 
7.5 Hz, COCH2CH2CH2N, 2H). 13C-NMR (126 MHz) CDCl3: δ = 
174.8 (C=O), 165.4 (d, 1JFC = 246.5 Hz, ArC), 137.8 (ArC), 133.5 
(ArC), 131.6 (ArC), 131.5 (ArC), 131.4 (ArC), 129.6 (d, 3JFC = 8.0 
Hz, ArC), 129.1 (ArC), 127.6 (d, 3JFC = 8.5 Hz, ArC), 126.7 (d, 2JFC 
= 16.0 Hz, ArC), 124.1 (d, 4JFC = 3.5 Hz, ArC), 115.4 (d, 2JFC = 
22.5 Hz, ArC), 50.2 (COCH2CH2CH2N), 31.3 (COCH2CH2CH2N), 
19.1 (COCH2CH2CH2N). HRMS-ESI (m/z) calculated for 
C16H14FNO [+Na] +: 278.0952, found: 278.0952. LCMS purity (UV) 
= 96 %, tR 12.30 min. 3j: 1H-NMR (500 MHz) CDCl3: δ = 7.42 – 
7.37 (m, ArH, 1H), 7.37 – 7.31 (m, ArH, 4H), 7.22 (d, 3JHH = 7.5 
Hz, ArH, 1H), 7.00 (d, 3JHH = 7.5 Hz, ArH, 1H), 6.98 – 6.94 (m, 
ArH, 1H), 3.76 (s, O-CH3, 3H), 3.26 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2CN, 2H), 2.34 (t,3JHH = 8.0 Hz, COCH2CH2CH2N, 
2H), 1.82 (p, 3JHH = 7.5 Hz, COCH2CH2CH2CN, 2H). 13C-NMR 
(126 MHz) CDCl3: δ = 174.7 (C=O), 156.4 (ArC), 137.3 (ArC), 
136.0 (ArC), 131.8 (ArC), 130.9 (ArC), 129.1 (ArC), 128.3 (ArC), 
128.0 (ArC), 127.8 (ArC), 127.2 (ArC), 120.6 (ArC), 110.7 (ArC), 
55.5 (O-CH3), 49.9 (COCH2CH2CH2N), 31.3 (COCH2CH2CH2N), 
19.2 (COCH2CH2CH2N). HRMS-ESI (m/z) calculated for 
C17H17NO2 [+Na] +: 290.1151, found: 290.1151. LCMS purity (UV) 
= 94 %, tR 11.65 min. 
 
1-(4’-Trifluoromethylbiphenyl-2-yl)pyrrolidin-2-one (3b) 
The general method was used on a 0.3 mmol scale with 4-
trifluoromethylbenzene diazonium tetrafluoroborate (1.2 mmol, 
0.31 g). The spectral data of 3b – 3e were concurrent with those 
reported.[16] 





The general method was used on a 0.3 mmol scale with 3-
trifluoromethylbenzene diazonium tetrafluoroborate (1.2 mmol, 
0.31 g). The title product was obtained as an oil (0.082 g, 90%).  
 
1-(4’-Methylbiphenyl-2-yl)pyrrolidin-2-one (3d) 
The general method was used on a 0.3 mmol scale with 4-
methylbenzene diazonium tetrafluoroborate (1.21 mmol, 0.25 g). 
The title product was obtained as an oil (0.051 g, 67%).  
 
1-(4’-Nitrobiphenyl-2-yl)pyrrolidin-2-one (3e) 
The general method was used on a 3.5 mmol scale with 4-
nitrobenzene diazonium tetrafluoroborate (11 mmol, 2.61 g). The 
title product was obtained as an oil (0.86 g, 87%).  
 
1-(4’-Hydroxybiphenyl-2-yl)pyrrolidin-2-one (3k) 
To a stirred solution of 1-(4’-methoxybiphenyl-2-yl)pyrrolidin-2-
one (1.6 mmol, 0.42 g) in DCM (10mL) was added 1M BBr3 (10 
mL) in DCM dropwise at 0oC under inert atmosphere. The 
reaction mixture was allowed to warm to ambient temperature and 
stirred for additional 16 h. The resulting mixture was carefully 
quenched with saturated sodium bicarbonate (50 mL) and the 
mixture was extracted with DCM (40mL x 2). The combined 
organic layer was dried (MgSO4) and concentrated under reduced 
pressure. The resulting crude product was triturated with diethyl 
ether overnight. The precipitate was collected by filtration to afford 
a grey solid (0.24 g, 58%). 1H-NMR (500 MHz) DMSO-D6: δ = 
7.36 – 7.29 (m, ArH, 3H), 7.26 – 7.22 (m, ArH, 1H), 7.10 (d, 3JHH 
= 8.7 Hz, 2H), 6.81 – 6.76 (m, ArH, 2H), 3.19 (t, 3JHH = 7.0 Hz, 
COCH2CH2CH2N, 2H), 2.23 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 
2H), 1.81 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 2H).13C-NMR (126 
MHz) DMSO-D6: δ = 174.7 (C=O), 157.3 (ArC), 137.3 (ArC), 139.5 
(ArC), 136.9 (ArC), 130.9 (ArC), 129.8 (ArC), 129.5 (ArC x 2), 
129.0 (ArC), 128.1 (ArC), 128.0 (ArC), 115.7 (ArC x 2), 49.9 
(COCH2CH2CH2N), 31.1 (COCH2CH2CH2N), 19.0 
(COCH2CH2CH2N). HRMS-ESI (m/z) calculated for C16H15NO2 




To a stirred solution of 1-(4’-nitrobiphenyl-2-yl)pyrrolidin-2-one 
(2.8 mmol, 0.8 g) in ethyl acetate (20mL) was added tin(ll) chloride 
dihydrate (14 mmol, 3.2 g) and the reaction was stirred at 70 0C 
overnight. The resulting mixture was neutralised with saturated 
sodium bicarbonate and extracted with ethyl acetate (40 mL x 2). 
The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure to afford the product as a 
white solid (0.62 g, 88%). 1H-NMR (500 MHz) DMSO-D6: δ = 7.34 
– 7.24 (m, ArH, 3H), 7.20 (d, 3JHH = 7.5 Hz, ArH, 1H), 6.96 (d, 3JHH 
= 7.5 Hz, ArH, 2H), 6.61 – 6.52 (m, ArH, 2H), 3.18 (t, 3JHH = 7.0 
Hz, COCH2CH2CH2N, 2H), 2.25 (t, 3JHH = 8.0 Hz, 
COCH2CH2CH2N, 2H), 1.82 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 
2H). 13C-NMR (126 MHz) CDCl3: δ = 175.7 (C=O), 145.9 (ArC), 
139.6 (ArC), 136.2 (ArC), 130.8 (ArC), 130.8 (ArC), 129.3 (ArC x 
2), 129.2(ArC), 128.4 (ArC), 128.0 (ArC), 127.8 (ArC), 115.0 (ArC 
x 2), 49.9 (COCH2CH2CH2N), 31.1 (COCH2CH2CH2N), 19.0 
(COCH2CH2CH2N). HRMS-ESI (m/z) calculated for C16H16N2O 





1-(4’-aminobiphenyl-2-yl)pyrrolidin-2-one (0.20 mmol, 0.050 g), 
maleic anhydride (0.24 mmol, 0.024 g) were dissolved in CHCl3 
(3 mL) and stirred for 2 h. The reaction mixture was concentrated 
under reduced pressure. To a stirred solution of the crude maleic 
acid in acetic anhydride (19.5 mmol, 2.0 g) was added sodium 
acetate (0.40 mmol, 0.033 g) and heated at reflux for 2 h. After 
cooling to ambient temperature, the reaction was quenched with 
water (20 mL) and extracted with ethyl acetate (20 mL x 2). The 
combined organic layers were dried (Na2SO4) and concentrated 
under reduced pressure. The crude mixture was purified by 
column chromatography (hexane/ethyl acetate over 0% - 10% 
gradient) to afford the title compound as a yellow solid (0.036g, 
54%).  1H-NMR (500 MHz) CDCl3: δ = 7.48 (d, 3JHH = 8.5 Hz, ArH, 
2H), 7.44 – 7.41 (m, ArH, 2H), 7.40 – 7.38 (m, ArH, 3H), 7.35 – 
7.31 (m, ArH, 1H), 6.88 (s, COCHCHCO, 2H), 3.25 (t, 3JHH = 7.0 
Hz, COCH2CH2CH2N, 2H), 2.45 (t, 3JHH = 8.0 Hz, 
COCH2CH2CH2N, 2H), 1.91 (p, 3JHH = 7.5 Hz, COCH2CH2CH2N, 
2H). 13C-NMR (126 MHz) CDCl3: δ = 175.8 (CH2NC=O), 169.4 
(CHCONCOCH), 138.7 (ArC), 136.4 (ArC), 134.3 (ArC x 2), 130.8 
(ArC), 130.7 (ArC), 129.1 (ArC x 2), 129.0 (ArC), 128.5 (ArC), 
128.2 (ArC), 125.8 (ArC x 2), 50.3 (COCH2CH2CH2N), 31.2 
(COCH2CH2CH2N), 19.0 (COCH2CH2CH2N). HRMS-ESI (m/z) 
calculated for C20H16N2O3 [+H] +: 333.1234, found: 333.1225. 




To a stirred solution of 1-(4’-aminobiphenyl-2-yl)pyrrolidin-2-one 
(0.38 mmol, 0.095 g) and triethylamine (0.38 mmol, 0.05 mL) in 
anhydrous DCM  (8 mL) was added chloroacetyl chloride (0.46 
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mmol, 0.052 g) dropwise at 0oC. The reaction mixture was 
allowed to warm to ambient temperature and stirred overnight. 
The reaction mixture was concentrated under reduced pressure. 
The residue was washed with washed with water (10 mL x 3) and 
the resulting precipitate was collected by filtration to afford the 
final product as a while solid (0.093g, 75%). 1H-NMR (500 MHz) 
CDCl3: δ = 8.55 (s, NH, 1H), 7.59 (d, 3JHH = 8.1 Hz, ArH, 2H), 7.41 
– 7.33 (m, ArH, 5H), 7.30 (d, 3JHH = 7.2 Hz, ArH, 1H), 4.17 (s, 
COCH2Cl, 2H), 3.27 (t, 3JHH = 7.0 Hz, COCH2CH2CH2N, 2H), 2.42 
(t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.90 (p, 3JHH = 7.5 Hz, 
COCH2CH2CH2N, 2H). 13C-NMR (126 MHz) CDCl3: δ = 175.7 
(CH2NC=O), 164.0 (NHC=O), 138.9 (ArC), 136.5 (ArC), 136.2 
(ArC), 135.8 (ArC), 130.8 (ArC), 128.7 (ArC x 2), 128.3 (ArC), 
128.2 (ArC), 119.9 (ArC x 2), 50.3 (COCH2CH2CH2N), 43.0 
(COCH2Cl), 31.2 (COCH2CH2CH2N), 19.0 (COCH2CH2CH2N). 
HRMS-ESI (m/z) calculated for C18H17ClN2O2 [+H] +: 329.1051, 
found: 329.1053. LCMS purity (UV) = 97%, tR 19.77 min. 
 
2-Chloro-N-[2'-(2-oxopyrrolidin-1-yl)biphenyl-4-yl]acetamide (3o) 
To a stirred solution of 1-(4’-aminobiphenyl-2-yl)pyrrolidin-2-one 
(0.39 mmol, 0.10 g) and triethylamine ( 1.98 mmol, 0.20 g) in 
anhydrous DCM  (10 mL) was added 3-chlorobenzoyl chloride 
(1.2 mmol, 0.21 g) and the reaction mixture was stirred overnight. 
The reaction mixture was concentrated under reduced pressure 
and the crude product was purified by column chromatography 
(DCM/methanol over 0% - 10% gradient) to afford the title product  
as a white amorphous solid (0.11 g, 72%). 1H-NMR (500 MHz) 
CDCl3: δ = 8.72 (s, NH, 1H), 7.95 – 7.90 (m, ArH, 1H), 7.79 (d, 
3JHH = 7.5 Hz, ArH, 1H), 7.72 (d, 3JHH = 8.5 Hz, ArH, 2H), 7.50 (dd, 
3,4JHH = 8.0, 2.0 Hz, ArH,  1H), 7.40 – 7.34 (m, ArH, 6H), 7.32 – 
7.26 (m, 1H), 3.31 (t, 3JHH = 7.0 Hz, ArH, COCH2CH2CH2N, 2H), 
2.38 (t, 3JHH = 8.0 Hz, COCH2CH2CH2N, 2H), 1.91 (p, 3JHH = 7.5 
Hz, COCH2CH2CH2N, 2H). 13C-NMR (126 MHz) CDCl3: δ = 175.8 
(CH2NC=O), 164.6 (NHC=O), 139.1 (ArC), 137.8 (ArC), 136.6 
(ArC), 136.1 (ArC), 135.1 (ArC), 134.7 (ArC), 131.8 (ArC), 130.9 
(ArC), 129.9 (ArC), 128.9 (ArC x 2), 128.5 (ArC), 127.6 (ArC), 
125.5 (ArC x 2), 50.5 (COCH2CH2CH2N), 31.2 (COCH2CH2CH2N), 
18.9 (COCH2CH2CH2N). HRMS-ESI (m/z) calculated for 
C23H19ClN2O2 [+H] +: 391.1208, found: 391.1199. LCMS purity 
(UV) = 91 %, tR 18.38 min. 
 
One-pot Reaction Towards 3a, 3c, and 3f 
This reaction was performed following the standard procedure by 
using 1-phenyl-2-pyrrolidinone (0.048 g, 0.3 mmol) and a mixture 
of 4-fluorobenzene diazonium tetrafluoroborate (84 mg, 0.40 
mmol), 4-methoxybenzene diazonium tetrafluoroborate (89 mg, 
0.40 mmol) and 3-trifluoromethylbenzene diazonium 
tetrafluoroborate (104 mg, 0.40 mmol). The products 3a, 3c and 
3f were obtained as a mixture with the ratio of 15%, 22% and 40% 
respectively (determined by LC-MS).  
 
Reaction with 2-Phenylpyridine 
2-Phenylpyridine (0.078 g, 0.50 mmol), 4-fluorodiazonium 
tetrafluoroborate (0.42 g, 2.0 mmol), palladium (II) acetate (0.011 
g, 0.05 mmol) and Ru(bpy)3Cl2.6H2O (0.009 g, 0.013 mmol) were 
suspended in degassed, anhydrous methanol (4 mL). Two 
fluorescent light bulbs (26 W) were placed on either side of the 
reaction vessel and the mixture was heated at reflux for 4 hours. 
The reaction mixture was allowed to cool to ambient temperature, 
diluted with ethyl acetate (40 mL) and washed with water (20 mL) 
and aqueous sodium sulphite (10%, 35 mL x 2). The combined 
aqueous layers were extracted with ethyl acetate (50 mL) and 
thereafter the combined organic layers were washed with brine 
(50 mL), dried (MgSO4) and concentrated under reduced 
pressure. The resulting crude material was purified by reversed 
phase chromatography (water/acetonitrile with 0.1% formic acid, 
5 min at 0%, 30%-90%). Starting material, 1-phenyl-2-
pyrrolidinone was recovered (0.008 g, 0.052 mmol) and five 
products were generated from this reaction: 
2-(4’-Fluorobiphenyl-2-yl)pyridine (5a) 
The title compound was obtained as a viscous oil (0.018 g, 16%). 
The spectral data were concurrent with those reported.[34] 
2-(4’-Methoxybiphenyl-2-yl)pyridine (5b)  
The title compound was obtained as a green/yellow oil (0.022 g, 
19%). The spectral data were concurrent with those reported.[34]  
2-(4,4’-Fluorobiphenyl-2,6-yl)pyridine (5c) 
The title product was obtained as a viscous oil (0.012 g, 8%). The 
spectral data were concurrent with those reported. [34]  
2-(4,4’-Fluoromethoxybiphenyl-2,6-yl)pyridine (5d) 
The title compound was obtained as a viscous oil (0.024 g, 
15%).1H-NMR (500 MHz) CDCl3: δ = 8.37 – 8.32 (m, ArH, 1H), 
7.49 (pt, 3JHH = 7.5 Hz, ArH, 1H), 7.45 – 7.42 (m, ArH, 1H), 7.38 
(d, 3JHH = 7.5 Hz, ArH, 1H), 7.35 – 7.30 (m, ArH, 1H), 7.07 – 7.03 
(m, ArH, 2H), 7.01 (d, 3JHH = 8.5 Hz, ArH, 2H), 6.95 – 6.92 (m, 
ArH, 1H), 6.87 – 6.81 (m, ArH, 3H), 6.69 (d, ArH, 3JHH = 8.5 Hz, 
2H), 3.75 (s, O-CH3, 3H). 13C-NMR (126 MHz) CDCl3: δ = 161.5 
(d, 1JFC = 246.0 Hz, ArC), 158.9 (ArC), 158.2 (ArC), 148.4 (ArC), 
141.5 (ArC), 140.8 (ArC), 137.5 (ArC), 135.2 (ArC), 133.7 (ArC), 
131.1 (d, 3JFC = 7.8 Hz; 2 x ArC), 130.7 (2 x ArC), 128.6 (ArC), 
129.1 (ArC), 128.2 (ArC), 126.9 (ArC), 126.6 (ArC), 121.0 (ArC), 
114.5 (d, 2JFC = 21.1 Hz; 2 x ArC), 113.2 (2 x ArC), 55.1 (O-CH3). 
HRMS-ESI (m/z) calculated for C24H18FNO [+H] +: 356.1445, 
found: 356.1444. LCMS purity (UV) = 93 %, tR 16.35 min. 
 




The title compound was obtained as a green/yellow oil (0.016 g, 
10%). The spectral data were concurrent with those reported.[34]  
 
Crystallographic Methods 
NUDT7 was expressed and purified as described previously[32,33] 
NUDT7 was crystallised in sitting drops at 20 °C by mixing 100 nL 
of 30 mg/mL protein in 10 mM Na-HEPES pH 7.5, 500 mM NaCl, 
5% glycerol with 50 nL of reservoir solution containing 0.1 M 
BisTris pH 5.5, 0.1 M ammonium acetate, and 6% (w/v) PEG 
10000. NUDT7 crystals were soaked with a mixture containing 
600 nL of 100 mM of the respective compound in DMSO with 
1200 nL of reservoir solution. Crystals were incubated overnight 
at room temperature and then harvested (without further 
cryoprotection) and flash-cooled in liquid nitrogen.  
All X-ray diffraction data were collected on beamline I04-1 at the 
Diamond Light Source. Diffraction data were automatically 
processed by software pipelines at the Diamond Light Source. [35] 
Initial refinement and map calculation was carried out with 
DIMPLE.[36] Ligand restraints were generated with ACEDRG.[37] 
Refinement and model building was performed with REFMAC[38] 
and COOT,[39] respectively. All structure determination steps were 
performed within the XChemExplorer[40] data management and 
workflow tool. Final models and structure factors have been 
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C-H activation reactions coupled with “nuisance effect” SNAr 
processes have been designed to “lose control” in order to make 
discrete libraries for immediate testing, by x-ray, versus targets 
of current interest. Although somewhat limited, these reactions 
may encourage others to try to reduce synthetic/work-up 
bottlenecks and use crystallography as a more routine analytical 
format for drug discovery. 
Institute and/or researcher Twitter usernames:  
